Aprea Therapeutics (APRE)
(Delayed Data from NSDQ)
$1.79 USD
+0.09 (5.29%)
Updated Aug 5, 2025 03:57 PM ET
After-Market: $1.79 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
APRE 1.79 +0.09(5.29%)
Will APRE be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for APRE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for APRE
Sutro Biopharma, Inc. (STRO) Reports Q4 Loss, Tops Revenue Estimates
Merus N.V. (MRUS) Reports Q4 Loss, Lags Revenue Estimates
APRE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's Why Aprea Therapeutics (APRE) Could be Great Choice for a Bottom Fisher
Aprea Therapeutics, Inc. (APRE) Reports Q3 Loss, Lags Revenue Estimates
XOMA Royalty (XOMA) Reports Q3 Loss, Tops Revenue Estimates
Other News for APRE
12 Health Care Stocks Moving In Wednesday's After-Market Session
Aprea Therapeutics (APRE) Reports Promising Data on APR-1051 for HPV+ Cancer | APRE Stock News
Aprea Therapeutics announces new preclinical data, update on APR-1051
Aprea Reports Anti-Proliferative Results and Promising Early-Stage Clinical Data for ...
Aprea Therapeutics announces new preclinical data, update on APR-1051